The Alpha-1 Project

The Alpha-1 Project: Investment
funding for potential Alpha-1 therapies

The Alpha-1 Foundation has invested more than $50 million to support Alpha-1 Antitrypsin research and programs. Through our traditional peer reviewed grants, the Foundation has funded research at 97 institutions in North America, Europe, the Middle East, and Australia.

In addition, the Foundation offers investment funding for translational research to develop new therapies for treating Alpha-1 lung and liver disease. Investment funding is available through our venture philanthropy subsidiary, The Alpha-1 Project, Inc.

The Alpha-1 Project (TAP) is a wholly-owned for profit subsidiary of the Alpha-1 Foundation singularly focused on providing critical funding and advice to speed the commercialization of therapies for the elimination of Chronic Obstructive Pulmonary Disease (COPD) and liver disease caused by Alpha-1 Antitrypsin Deficiency (Alpha-1).

TAP will focus funding into highly promising drug therapies or devices in the translational research or clinical trial stage of development to speed the commercialization of these therapies. It will leverage the experience and scientific knowledge of the Alpha-1 Foundation as well as the drug therapy and device commercialization expertise of large pharmaceutical and biotechnology companies.

Grant or Investment funding?

 Generally, if you are in academia, apply for a grant. See our Research Grant Opportunities.

A biotechnology or pharmaceutical company, or any entity hoping to commercialize a product, should apply through The Alpha-1 Project.

If you are unsure, contact David Fernandez, Manager of Research Administration, at dfernandez@alpha-1foundation.org or at 305-567-9888 Ext. 242.

The Alpha-1 Project seeks partnerships with individual donors, patients, academia, and pharmaceutical and biotechnology companies to eliminate the effects of Chronic Obstructive Pulmonary Disease (COPD) and liver disease caused by Alpha-1. We believe that by building upon our significant internal scientific resources, leveraging our partnerships and using our unique, venture capital-like approach to evaluating and making targeted investments, we will speed the development of new drug therapies and devices to combat this condition.

For more information, see The Alpha-1 Project.